Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial.
Conrad-Amadeus VoltinJasmin MettlerLutz van HeekHelen GoergenHorst MüllerChristian BauesUlrich KellerJulia MeissnerKarolin Trautmann-GrillAndrea KerkhoffMichael FuchsStephanie SasseBastian von TresckowMarkus DietleinPeter BorchmannAndreas EngertCarsten KobePaul J BröckelmannPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our study showed that nivolumab-based first-line treatment leads to rapid, near-complete reduction of tumor metabolism in early-stage unfavorable Hodgkin lymphoma. Thus, PET-derived biomarkers might allow reduction or even omission of chemotherapy and radiotherapy. Furthermore, MTV and TLG could be also used to optimize immune checkpoint-targeting treatments in other cancers.
Keyphrases
- hodgkin lymphoma
- phase ii
- early stage
- open label
- clinical trial
- phase iii
- placebo controlled
- double blind
- pet ct
- computed tomography
- positron emission tomography
- locally advanced
- radiation therapy
- study protocol
- cancer therapy
- pet imaging
- sentinel lymph node
- radiation induced
- randomized controlled trial
- replacement therapy
- lymph node
- young adults
- drug delivery
- loop mediated isothermal amplification